To the Editor In an update of their randomized clinical trial, Dr D’Amico and colleagues1 reported that combined radiation therapy (RT) and androgen deprivation therapy (ADT) was no longer associated with an overall survival benefit among 206 men with unfavorable localized prostate cancer after a median of 16.6 years.
These observations are inconsistent with 2 prior reports of this trial and with the results of multiple randomized trials (involving >8000 men) that have consistently demonstrated a survival benefit with the addition of ADT for men receiving RT with intermediate, high-risk, and locally advanced prostate cancer.2
Voog JC, Smith MR, Efstathiou JA. Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2016;315(10):1054–1055. doi:10.1001/jama.2015.17567